{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-028715","form_type":"8-K","ticker":"XAIR","cik":"0001641631","company_name":"Beyond Air, Inc.","filed_at":"2023-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.654021+00:00","generated_at":"2026-06-11T09:27:00.410401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Beyond Air Q1 FY2024 revenue $0.1M (first commercial); net loss $14.1M; secured $40M debt facility","bullets":["Revenue of $0.1M from commercial LungFit PH sales; cost of revenue $0.3M.","Net loss $14.1M ($0.45 loss per share) vs $10.9M ($0.37) YoY; R&D $4.7M, G&A $10.9M.","Secured up to $40M debt financing from Avenue Capital; $17.5M drawn; cash $57M.","In excess of $1M annual commercial LungFit PH contracts; CE Mark expected by end 2023.","Agreed with FDA on VCAP study for 2023-24 winter; added nNOS program for autism."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-028715","json":"https://secwatch.observer/filing/0001493152-23-028715.json","markdown":"https://secwatch.observer/filing/0001493152-23-028715.md","text":"https://secwatch.observer/filing/0001493152-23-028715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641631/000149315223028715/0001493152-23-028715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641631/000149315223028715/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:27:00.410401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44d224ad8efae2809d807fbe4c93e17cb7cfe2ff","claim":"Beyond Air, Inc. reported the fiscal quarter ended June 30, 2023 results: revenue $0.1 million, net income ($14.1) million, EPS ($0.45) per share, basic and diluted.","evidence_excerpt":"a first-in-human study of nNOS for treatment of ASD in 2025 Financial Results for the Fiscal Quarter Ended June 30, 2023 Revenues for the three months ended June 30, 2023 were $0.1 million compared to zero for the quarter ended June 30, 2022. Cost of revenue of $0.3 million was recognized for the three months ended June 30, 2023, compared to $0 for the three months","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641631/000149315223028715/0001493152-23-028715-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended June 30, 2023"},{"label":"Revenue","value":"$0.1 million"},{"label":"Net income","value":"($14.1) million"},{"label":"EPS","value":"($0.45) per share, basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}